Novo Nordisk (NOVOB.DK) shares are gaining 3.0% after the company raised its sales forecast for 2023 on strong demand for Ozempic and Wegovy medicines.
- Operating profit at constant exchange rates +40% to +46%, previously expected +31% to +37%, Bloomberg estimated +37.5%
- Sales at constant exchange rates +32% to +38%, previously expected +27% to +33%, Bloomberg estimated +31.7%.
Morning wrap: Tech sector sell-off (06.02.2026)
Amazon shares tumble 10% as investors recoil at the price of AI dominance
Disaster for Volvo shares. Is this the end of an iconic brand?
Stock of the week: Alphabet is no longer just a search engine (05.02.2026)